A reduction in repurchases under, or the completion of, our share repurchase programs could have a negative effect on our stock price.Furthermore, we may not be able to achieve the full strategic and financial benefits expected to result from transactions, or the benefits may be delayed or not occur at all.Our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.These third-parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products.We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any personnel will not have a material impact on our financial condition and results of operations.Whether or not we have complied with the law, an investigation or litigation related to alleged unlawful conduct could increase our expense, damage our reputation, divert management time and attention and adversely affect our business.Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.Use of AI based software may lead to the release of confidential proprietary information which may impact our ability to realize the benefit of our intellectual property.Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions.Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost.Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources.Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation.Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect, when they impact vendors, customers or companies, including vendors, suppliers and other companies in our supply chain.There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance.Changes in flexible working arrangements could impact employee retention, employees'productivity and morale, strain our technology resources and introduce operational risks.Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge.For additional information on our collaboration arrangements, please read Note 16, Collaborative and Other Relationships, to our condensed consolidated financial statements included in this report.For additional information, please read Note 18, Litigation, to our condensed consolidated financial statements included in this report and the discussion under Results of Operations-Product Revenue-Multiple Sclerosis (MS) below.Decreased $159.7 million or 7.3% • Cost of sales decreased $91.1 million, or 12.1% • SG & A expense decreased $29.9 million, or 4.7% • The decrease in cost of sales was primarily due to the write-off of approximately $275.0 million during the first quarter of 2022 related to ADUHELM inventory.48 Table of ContentsRESULTS OF OPERATIONSREVENUEThe following revenue discussion should be read in conjunction with Note 4, Revenue, to our condensed consolidated financial statements included in this report.• U. S. SPINRAZA revenue decreased $16.6 million, from $163.3 million in 2022 to $146.7 million in 2023, or 10.2%, primarily due to a decrease in sales volumes resulting from unfavorable channel dynamics and the impact of loading dose dynamics.For additional information on our collaboration arrangements with Eisai, please read Note 16, Collaborative and Other Relationships, to our condensed consolidated financial statements included in this report.For additional information on our collaboration arrangements with Genentech, including information regarding the pre-tax profit-sharing formula and its impact on future revenue from anti-CD 20 therapeutic programs, please read Note 16, Collaborative and Other Relationships, to our condensed consolidated financial statements included in this report.For additional information on our revenue reserves, please read Note 4, Revenue, to our condensed consolidated financial statements included in this report.For additional information on our collaboration arrangements with Eisai, please read Note 16, Collaborative and Other Relationships, to our condensed consolidated financial statements included in this report.For additional information on the amortization and impairment of our acquired intangible assets, please read Note 6, Intangible Assets and Goodwill, to our condensed consolidated financial statements included in this report.For additional information on our cost saving initiatives, please read Note 3, Restructuring, to our condensed consolidated financial statements included in this report.For additional information on our income taxes, please read Note 14, Income Taxes, to our condensed consolidated financial statements included in this report.For additional information on the valuation allowance and our collaboration agreement with Neurimmune, please read Note 17, Investments in Variable Interest Entities, to our condensed consolidated financial statements included in this report.The change in working capital reflects a decrease in total current assets of approximately $28.7 million and a decrease in total current liabilities of approximately $257.9 million.For additional information on our collaboration arrangements, please read Note 16, Collaborative and Other Relationships, to our condensed consolidated financial statements included in this report.NEW ACCOUNTING STANDARDSFor a discussion of new accounting standards please read Note 1, Summary of Significant Accounting Policies, to our condensed consolidated financial statements included in this report.